What is HC Wainwright’s Forecast for RARE FY2026 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – HC Wainwright issued their FY2026 earnings estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Thursday, November 5th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will earn ($1.51) per share for the year. HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2026 earnings at $2.35 EPS, Q1 2027 earnings at $0.63 EPS, Q2 2027 earnings at $1.38 EPS, Q3 2027 earnings at $1.73 EPS, Q4 2027 earnings at $2.64 EPS and FY2027 earnings at $6.38 EPS.

RARE has been the subject of a number of other reports. Wells Fargo & Company upped their price objective on Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. Wedbush reduced their target price on Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a “neutral” rating on the stock in a report on Wednesday, November 4th. Royal Bank Of Canada cut Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a report on Thursday, September 3rd. Barclays lowered their price target on Ultragenyx Pharmaceutical from $35.00 to $32.00 and set an “overweight” rating for the company in a research report on Thursday, November 5th. Finally, Guggenheim dropped their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $29.79.

Ultragenyx Pharmaceutical Stock Up 6.4%

NASDAQ:RARE opened at $16.41 on Monday. The company has a market cap of $1.62 billion, a P/E ratio of -3.16 and a beta of 0.37. Ultragenyx Pharmaceutical has a fifty-two week low of $12.73 and a fifty-two week high of $39.89. The firm’s 50 day moving average is $15.84 and its two-hundred day moving average is $22.68.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The company had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. During the same quarter in the previous year, the company earned ($1.81) earnings per share. The business’s revenue was up 8.2% on a year-over-year basis.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. raised its holdings in Ultragenyx Pharmaceutical by 295.4% in the third quarter. Assenagon Asset Management S.A. now owns 477,869 shares of the biopharmaceutical company’s stock valued at $7,182,000 after acquiring an additional 357,005 shares in the last quarter. BlackRock Inc. acquired a new position in Ultragenyx Pharmaceutical in the second quarter valued at approximately $355,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth $6,397,000. Deutsche Bank AG acquired a new stake in Ultragenyx Pharmaceutical in the second quarter worth $5,503,000. Finally, Corient Private Wealth LP bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $4,644,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,066 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer directly owned 89,229 shares of the company’s stock, valued at approximately $1,362,526.83. The trade was a 7.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock worth $127,561 in the last three months. 5.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders.

Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.